1. Catalog
  2. OnDemand: February 2026 Grand Rounds: Host-Diet-Gu ...
OnDemand: February 2026 Grand Rounds: Host-Diet-Gut Microbiome Interactions
Create Account
Availability
On-Demand
Cost
Member: $0.00
Non-Member: $50.00
Credit Offered
1 AMA PRA Category 1 Credit
  • Overview
  • Accreditation
  • Disclosures
  • Recommended
Description
This presentation explores how interactions between diet, the gut microbiome, and the human host influence energy balance and obesity. It highlights emerging evidence that diet-driven changes in gut microbes can alter energy availability to the host, with implications for obesity prevention and treatment.

Learning Objectives
  • Describe the mechanisms by which diet–gut microbiome interactions influence host energy availability, energy balance, and obesity risk.
  • Interpret emerging research on diet-induced changes in the gut microbiome to distinguish clinically relevant findings from preliminary or exploratory data.
  • Apply microbiome-informed dietary principles when counseling patients on obesity prevention and treatment strategies

Faculty
Karen D. Corbin, PhD, RD, FTOS
Associate Investigator and Obesity Program Lead

Commercial Support
No commercial support was received for this activity. 
The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Obesity Society designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Date of Release: March 1, 2026
Date of Expiration: December 31, 2028
ACCME Activity ID: 203584532
Disclosure Statement

The Obesity Society adheres to the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Individuals in a position to control the content of this activity, including speakers, planners, and reviewers, have disclosed all relevant financial relationships. All relevant conflicts of interest have been mitigated prior to the activity.

For additional information regarding TOS disclosure and mitigation policies, view the Disclosure & Integrity Policy.
Individual Role Relevant Financial Relationships
 Karen Corbin, PhD, RD, FTOS Speaker Research: Boehringer Ingelheim, BPG Bio, Eli Lilly, Novo Nordisk.
Sriram Machenini, MD Planner
No relevant financial relationships.
TOS CME Oversight Committee Reviewer Committee No relevant financial relationships.
Powered By